PineBridge Investments L.P. increased its position in shares of Cambrex Corp. (NYSE:CBM) by 4.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,056 shares of the company’s stock after buying an additional 171 shares during the period. PineBridge Investments L.P.’s holdings in Cambrex Corp. were worth $210,000 as of its most recent filing with the SEC.
Other large investors also recently made changes to their positions in the company. Acrospire Investment Management LLC raised its stake in shares of Cambrex Corp. by 149.0% in the second quarter. Acrospire Investment Management LLC now owns 2,674 shares of the company’s stock worth $138,000 after buying an additional 1,600 shares during the last quarter. Intrust Bank NA bought a new stake in shares of Cambrex Corp. during the second quarter worth $206,000. Advisors Asset Management Inc. acquired a new position in Cambrex Corp. during the second quarter worth approximately $216,000. Teacher Retirement System of Texas increased its position in Cambrex Corp. by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 4,413 shares of the company’s stock worth $228,000 after buying an additional 533 shares during the period. Finally, Pinnacle Financial Partners Inc. acquired a new position in Cambrex Corp. during the second quarter worth approximately $256,000. Institutional investors own 99.46% of the company’s stock.
Cambrex Corp. (NYSE:CBM) opened at 45.055 on Wednesday. The firm’s 50-day moving average is $45.28 and its 200-day moving average is $47.69. The stock has a market cap of $1.45 billion, a P/E ratio of 22.778 and a beta of 1.45. Cambrex Corp. has a 52-week low of $29.50 and a 52-week high of $59.41.
Cambrex Corp. (NYSE:CBM) last released its earnings results on Thursday, July 28th. The company reported $0.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.09. Cambrex Corp. had a net margin of 13.97% and a return on equity of 24.86%. The business earned $118.22 million during the quarter, compared to analyst estimates of $114.85 million. During the same quarter in the prior year, the firm earned $0.63 earnings per share. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. Equities research analysts predict that Cambrex Corp. will post $2.56 earnings per share for the current year.
Separately, Zacks Investment Research downgraded shares of Cambrex Corp. from a “strong-buy” rating to a “hold” rating in a research report on Tuesday.
In other news, Director William B. Korb sold 3,420 shares of the company’s stock in a transaction on Monday, July 11th. The shares were sold at an average price of $55.00, for a total transaction of $188,100.00. Following the completion of the sale, the director now owns 23,982 shares of the company’s stock, valued at $1,319,010. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 2.63% of the company’s stock.
Cambrex Corp. Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corp. (NYSE:CBM).
Receive News & Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.